Jeffrey L. Anderson, MD, FACC, FAHA, Chair 

Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect 

Alice K. Jacobs, MD, FACC, FAHA, Immediate Past Chair 2009–2011 [§§][1]

Sidney C. Smith, Jr, MD, FACC, FAHA, Past Chair 2006–2008 [§§][1]

Cynthia D. Adams, MSN, APRN-BC, FAHA[§§][1]

Nancy M

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Ambulatory blood pressure monitoring (ABPM) is being used increasingly in both clinical practice and hypertension research. Although there are many guidelines that emphasize the indications for ABPM, there is no comprehensive guideline dealing with all aspects of the technique. It was agreed at a consensus meeting on ABPM in Milan in 2011 that the 34 attendees should prepare a comprehensive position paper on the scientific evidence for ABPM.This position paper considers the historical background, the advantages and limitations of ABPM, the threshold levels for practice, and the cost-effectiveness of the technique. It examines the need for selecting an appropriate device, the accuracy of devices, the additional information and indices that ABPM devices may provide, and the software requirements.At a practical level, the paper details the requirements for using ABPM in clinical practice, editing considerations, the number of measurements required, and the circumstances, such as obesity and arrhythmias, when particular care needs to be taken when using ABPM.The clinical indications for ABPM, among which white-coat phenomena, masked hypertension, and nocturnal hypertension appear to be prominent, are outlined in detail along with special considerations that apply in certain clinical circumstances, such as childhood, the elderly and pregnancy, and in cardiovascular illness, examples being stroke and chronic renal disease, and the place of home measurement of blood pressure in relation to ABPM is appraised.The role of ABPM in research circumstances, such as pharmacological trials and in the prediction of outcome in epidemiological studies is examined and finally the implementation of ABPM in practice is considered in relation to the issue of reimbursement in different countries, the provision of the technique by primary care practices, hospital clinics and pharmacies, and the growing role of registries of ABPM in many countries.

/pdf/european-society-of-hypertension-position-paper-on-5gl2xrb6pc.pdf

European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring

Theodore G. Ganiats, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre D. Adams, Charles R. Bridges, Donald E. Casey, Jr, Steven M. Ettinger, Francis M. Fesmire, 2012 Writing Committee Members, Hani Jneid, Jeffrey L. Anderson, R. Scott Wright, Cynthia Foundation/American Heart Association Task Force on Practice Guidelines Cardiology and Replacing the 2011 Focused Update): A Report of the American College of ST-Elevation Myocardial Infarction (Updating the 2007 Guideline − Unstable Angina/Non 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With

Accf/aha task force members

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.013

/pdf/2012-accf-aha-acp-aats-pcna-scai-sts-guideline-for-the-3rcj2i2kf5.pdf

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease

Response to Letter to editor "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults".

In the main Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) report, we investigated outcomes in 15 245 high-risk hypertensive subjects treated with valsartan- or amlodipine-based regimens In this report, we analyzed outcomes in 7080 patients (464%) who, at the end of the initial drug adjustment period (6 months), remained on monotherapy Baseline characteristics were similar in the valsartan (N=3263) and amlodipine (N=3817) groups Time on monotherapy was 32 years (78% of treatment exposure time) The average in-trial blood pressure was similar in both groups Event rates in the monotherapy group were 16% to 39% lower than in the main VALUE trial In the first analysis, we censored patients when they discontinued monotherapy ("censored"); in the second, we counted events regardless of subsequent therapy (intention-to-treat principle) We also assessed the impact of duration of monotherapy on outcomes No difference was found in primary composite cardiac end points, strokes, myocardial infarctions, and all-cause deaths with both analyses Heart failure in the valsartan group was lower both in the censored and intention-to-treat analyses (hazard ratios: 063, P=0004 and 078, P=0045, respectively) Longer duration of monotherapy amplified between-group differences in heart failure New-onset diabetes was lower in the valsartan group with both analyses (odds ratios: 078, P=0012 and 082, P=0034) Thus, despite lower absolute event rates in monotherapy patients, the relative risks of heart failure and new-onset diabetes favored valsartan Moreover, these findings support the feasibility of comparative prospective trials in lower-risk hypertensive patients

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy

BackgroundEvaluation of combination therapy with antihypertensive agents by clinic blood pressure (BP) measurements may yield results that differ from out-of-office BP readings. This is of clinical relevance because out-of-office BP values are of prognostic importance. We studied the effects of comb

Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension.

Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinic BP in 400 patients with systemic hypertension: results from a pivotal multinational trial

Willie Oigman

Papers

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy

Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension.

Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinic BP in 400 patients with systemic hypertension: results from a pivotal multinational trial